Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity's Gedatolisib Phase 3 Trial Achieves Primary Endpoint in PIK3CA Mutant Breast Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$140
Mkt Cap
$6.074B
52W Low
$9.51
52W High
$129.09
52W Position info
1372% above low
Off High info
at 52W high
Rel. Volume info
2.8× avg
Market data snapshot near publication time

CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.8× avg).

Summary

Celcuity reported positive Phase 3 trial results for gedatolisib in PIK3CA mutant breast cancer, showing significant improvement in progression-free survival and paving the way for an sNDA submission.


Key Events · Product Development and Regulatory · CELC

  • Positive Phase 3 Trial Results

    The PIK3CA mutant cohort of the VIKTORIA-1 trial for gedatolisib achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care.

  • Expanded Market Potential

    This success in the PIK3CA mutant population significantly broadens the addressable market for gedatolisib, complementing the existing FDA Priority Review for the PIK3CA wild-type cohort.

  • Planned sNDA Submission

    Celcuity intends to submit these positive data to the FDA as a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting.

  • Favorable Safety Profile

    Both gedatolisib regimens were generally well tolerated with manageable safety profiles and no new safety signals.


Analysis · CELC · Industrial Applications And Services

Celcuity Inc. announced highly positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib. The drug demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both triplet and doublet regimens, with a manageable safety profile. This success significantly expands the potential market for gedatolisib, building on the existing FDA Priority Review for the PIK3CA wild-type cohort. The company plans to submit these data for a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting, marking a critical step towards broader commercialization and addressing a significant unmet medical need in advanced breast cancer.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $140.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $9.51 to $129.09. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $64.37 info
Change: -$1.95 (-3%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $64.37 info
Change: -$14.63 (-19%) info
Market Cap: $3.162B info